Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;21(11):662-675.
doi: 10.1038/s41585-024-00876-w. Epub 2024 May 2.

Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma

Chengheng Liao #  1 , Lianxin Hu #  1 , Qing Zhang  2   3
Affiliations
Review

Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma

Chengheng Liao et al. Nat Rev Urol. 2024 Nov.

Abstract

The distinct pathological and molecular features of kidney cancer in adaptation to oxygen homeostasis render this malignancy an attractive model for investigating hypoxia signalling and potentially developing potent targeted therapies. Hypoxia signalling has a pivotal role in kidney cancer, particularly within the most prevalent subtype, known as renal cell carcinoma (RCC). Hypoxia promotes various crucial pathological processes, such as hypoxia-inducible factor (HIF) activation, angiogenesis, proliferation, metabolic reprogramming and drug resistance, all of which contribute to kidney cancer development, growth or metastasis formation. A substantial portion of kidney cancers, in particular clear cell RCC (ccRCC), are characterized by a loss of function of Von Hippel-Lindau tumour suppressor (VHL), leading to the accumulation of HIF proteins, especially HIF2α, a crucial driver of ccRCC. Thus, therapeutic strategies targeting pVHL-HIF signalling have been explored in ccRCC, culminating in the successful development of HIF2α-specific antagonists such as belzutifan (PT2977), an FDA-approved drug to treat VHL-associated diseases including advanced-stage ccRCC. An increased understanding of hypoxia signalling in kidney cancer came from the discovery of novel VHL protein (pVHL) targets, and mechanisms of synthetic lethality with VHL mutations. These breakthroughs can pave the way for the development of innovative and potent combination therapies in kidney cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). - PubMed - DOI
    1. Bhatt, J. R. & Finelli, A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat. Rev. Urol. 11, 517–525 (2014). - PubMed - DOI
    1. Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009 (2017). - PubMed - DOI
    1. Moch, H. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs – part a: renal, penile, and testicular tumours. Eur. Urol. 82, 458–468 (2022). - PubMed - DOI
    1. Zhang, Q., Yan, Q., Yang, H. & Wei, W. Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine. Genes. Dis. 6, 328–332 (2019). - PubMed - PMC - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources